US EditionForesee Pharmaceuticals announces reaching a significant milestone, of complete enrollment of its Phase 3 Casppian trial for patients with Central Precocious Puberty (CPP) - PressReach
Summary by pressreach.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Foresee Pharmaceuticals announces reaching a significant milestone, of complete enrollment of its Phase 3 Casppian trial for patients with Central Precocious Puberty (CPP) - PressReach
A multicenter, multinational Phase 3 Casppian study will evaluate the efficacy and safety of leuprolide mesylate (FP-001) 42 mg controlled-release in patients with CPP. Gonadotropin-releasing hormone (GnRH) agonists, including leuprolide, are the most widely used treatment for CPP. Topline results from this pivotal trial are expected by the end of 2025. Based on the successful outcomes of the study completion by mid-2026, Foresee plans to submit…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
